Clinical Trials Logo

Solitary Fibrous Tumor clinical trials

View clinical trials related to Solitary Fibrous Tumor.

Filter by:
  • None
  • Page 1

NCT ID: NCT03840772 Recruiting - Clinical trials for Solitary Fibrous Tumor

Eribulin in Advanced Solitary Fibrous Tumor

ERASING
Start date: July 17, 2019
Phase: Phase 2
Study type: Interventional

Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin

NCT ID: NCT02261207 Completed - Clinical trials for Solitary Fibrous Tumor

Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor

Start date: November 2014
Phase: Phase 2
Study type: Interventional

This is an investigator initiated, open label, prospective, non-randomized, phase II trial aimed at evaluating the activity of Axitinib in progressive VEGFR2 and/or PDGFRB positive advanced Solitary Fibrous Tumor (SFT) patients. Patients with a documented and centrally reviewed pathologic and radiologic diagnosis of progressive VEGFR2 and/or PDGFRB positive advanced SFT may enter in the study. Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.

NCT ID: NCT02066285 Completed - Clinical trials for Extraskeletal Myxoid Chondrosarcoma

Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

Start date: June 2014
Phase: Phase 2
Study type: Interventional

Phase II, open-label, non-randomized, international multicenter clinical trial with two strata (SFT and EMC). 8 sites in Spain, 5 sites in Italy and 5 sites in France. Patients will receive oral pazopanib at 800 mg once daily continuously. Patients will continue to receive treatment until there is evidence of progressive disease, unacceptable toxicity, non-compliance, withdrawn consent or investigator decision. The main goal is to determine the objective response rate (ORR) (confirmed complete response [CR] and partial response [PR]) in patients with unresectable, locally advanced or metastatic solitary fibrous tumor and extraskeletal myxoid chondrosarcoma, using Choi and RECIST 1.1 criteria respectively.